The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...